# ABLi Therapeutics, Inc. — Form D

ABLi Therapeutics, Inc. of ATLANTA, GA, a company, filed a Form D exempt-offering notice with the SEC on 2026-01-13. The offering totals $1.0M, of which $1.0M was reported sold. Industry: Pharmaceuticals.

## Offering

- Filed: 2026-01-13
- Form: D
- Accession: 0002104142-26-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $1.0M
- Amount sold: $1.0M
- Investors: 10
- Date of first sale: 2025-09-15
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-569754

## Issuer

- Name: ABLi Therapeutics, Inc.
- CIK: 0002104142
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2025
- Address: 3350 RIVERWOOD PKWY SE, ATLANTA, GA, 30339
- Phone: 917-494-0831

## Officers, directors & promoters (5)

| Name | Role | Location |
| --- | --- | --- |
| Anastasia H. Daifotis | Director | Atlanta, GA |
| Milton H. Werner | Director | Atlanta, GA |
| Jeffrey H. Young | Director | Atlanta, GA |
| Garth H. Lees-Rolfe | Executive Officer | Atlanta, GA |
| Milton H. Werner | Executive Officer | Atlanta, GA |

## More

- [CIK 2104142 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2104142&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0002104142-26-000001.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.